Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients. (30th June 2021) - Lorenc, Z Paul; Adelglass, Jeffrey M; Avelar, Rui L; Baumann, Leslie; Beer, Kenneth R; Cohen, Joel L; Cox, Sue Ellen; Dayan, Steven H; Dover, Jeffrey S; Downie, Jeanine B; Draelos, Zoe Diana; Goldman, Mitchel P; et al.